Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara Moorhouse will join the Board of Medica as a Non-Executive Director on 1 July 2021. Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerized tomography), ultrasound, and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland.

Barbara Moorhouse will serve as the Senior Independent Director and Chair of the Audit Committee. As previously announced, Steve Whittern, Senior Independent Non-Executive Director and Chair of the Audit Committee, will stand down from the Board ahead of the Annual General Meeting on 16 June 2021.

Barbara has extensive business and management experience in the private, public, and regulated sectors. In the private sector, Barbara has held a series of strategic, commercial, and finance roles, including being Chief Finance Officer for two international listed IT companies – Kewill Systems plc and Scala Business Solutions NV, Group Finance Director at Morgan Sindall plc, and Regulatory Director at South West Water.

In the public sector, she has been Director General at the Ministry of Justice and the Department for Transport and Chief Operating Officer at Westminster City Council. Barbara has been a Trustee and Chair of the Audit Committee for Guy’s & St Thomas’ Charity and a Non-Executive Director of the NHS West Hampshire Clinical Commissioning Group. She is Non-Executive Director at Balfour Beatty plc, Non-Executive Director and Chair of the Audit Committee at Aptitude Software Group plc and Chair of the Rail Safety & Standards Board. Barbara is currently Non-Executive Director at Agility Trains (East) Ltd but is stepping down this month having been on the board since 2015.

Roy Davis, Chairman of Medica, said: “We are delighted to have someone of Barbara’s expertise and stature join the Board of Medica. Barbara is a seasoned Non-Executive Director and brings significant experience from both the private and public sectors. Coupled with her extensive background in the most senior of finance positions in large scale, highly complex, and fast-growing organizations, Barbara will further strengthen Medica’s Board. I very much look forward to working with her.”

Commenting on her appointment, Barbara Moorhouse added: “I am very pleased to be joining the Board of such an exciting and rapidly-growing company with a compelling strategy in place. I am looking forward to engaging with the Board and the management team and using my expertise to help implement this strategy.”

 

SourceMedica

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.